DESIGNATED COMPOUNDS Sample Clauses
The "Designated Compounds" clause defines which specific chemical compounds are covered or referenced within the agreement. Typically, this clause lists or describes the compounds by name, structure, or other identifying characteristics, ensuring all parties are clear about the substances involved. By precisely identifying the relevant compounds, the clause prevents ambiguity and potential disputes over the scope of rights, obligations, or restrictions related to those compounds.
DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Selected Compounds for each Target by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A (or the delivery of the corresponding notice regarding Primary Compound Activity by OGS in accordance with ATTACHMENT A), OGS shall notify NeoGenesis whether it will classify any Selected Compounds (or any derivative compound(s) of such Selected Compounds) as the basis for optimisation so as to yield a candidate for drug development based on OGS's good faith evaluation of *=CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. the satisfaction of the Success Criteria by such Selected Compound (or any derivative compound(s) of such Selected Compounds) (each, a DESIGNATED COMPOUND). If OGS does not identify any Designated Compound(s) within such period, the license granted OGS shall terminate and be of no further force or effect with respect to the applicable Target, and no further payment from OGS shall be due with respect to such Target.
(b) Within thirty (30) days of the Effective Date, NeoGenesis shall update ATTACHMENT D. Thereafter, within thirty (30) days following receipt of notification from OGS identifying Designated Compounds, NeoGenesis shall amend ATTACHMENT D to identify any applicable NeoGenesis Patent Rights not previously identified to OGS. For the avoidance of doubt, to the extent that ATTACHMENT D is not updated to include any NeoGenesis Patent Rights that OGS requires to exercise its license under Section 3.1, NeoGenesis agrees that it shall not have any action against OGS in relation thereto and shall automatically amend ATTACHMENT D to include such NeoGenesis Patent Rights.
DESIGNATED COMPOUNDS. In the event that Licensee determines to cease the development of a Designated Compound prior to obtaining Regulatory Approval therefor, Licensee shall have the right to substitute another Licensed Compound for such Designated Compound upon written notice to Licensor (which written notice will identify both the “new” Designated Compound and the Designated Compound that is being “deselected”); provided that, at no time will there be more than [**] Designated Compounds.
DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Primary Active Compounds Report for a Target by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A, CUSTOMER shall notify NeoGenesis whether it will classify any Primary Active Compounds as a Selected Compound for further study or optimization. If CUSTOMER does not identify any Selected Compound(s) within such period, the license granted CUSTOMER under Section 3.1 shall terminate with respect to the applicable Target and be of no further force or effect with respect to such Target, and no further payment from CUSTOMER shall be due with respect to such Target.
(b) Within [*] following delivery of the Final Target Report for a Target by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A, CUSTOMER shall notify NeoGenesis whether * = CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. it will classify any of the Selected Compounds as a "DESIGNATED COMPOUND" for further research and development in the CUSTOMER'S R&D Program; PROVIDED, that CUSTOMER may not select more than [*] Designated Compounds in respect of each Target. If CUSTOMER does not identify any Designated Compound(s) within such period, the license granted CUSTOMER with respect to the applicable Target shall terminate and be of no further force or effect with respect to the applicable Target, and no further payment from CUSTOMER shall be due with respect to such Target. Notwithstanding the foregoing, CUSTOMER may at any time during CUSTOMER's R&D Program designate a compound from a CUSTOMER supplied library as a Designated Compound and subject to the milestone payments payable pursuant to Section 4.2(b) and royalty payments pursuant to Section 4.3(b), shall continue to have the license granted CUSTOMER pursuant to Section 3.1.
(c) Within [*] following receipt of notification from CUSTOMER identifying Designated Compounds, NeoGenesis shall amend ATTACHMENT C to identify any applicable NeoGenesis Patent Rights not previously identified to CUSTOMER. Thereafter, NeoGenesis shall update ATTACHMENT C as necessary to identify any applicable NeoGenesis Patent Rights not previously identified to CUSTOMER
DESIGNATED COMPOUNDS. (a) Within [*] following the delivery of the Final Target Report for each Target by NeoGenesis in accordance with Section 2.4 and ATTACHMENT A, Mitsubishi shall notify NeoGenesis whether it will classify any Candidate Compound C (or any derivative compound(s) of such Candidate Compound C) as candidates for drug development based on Mitsubishi's good faith evaluation of the satisfaction of the Success Criteria by such Candidate Compound C (or any derivative compound(s) of such Candidate Compound C) (each, a DESIGNATED COMPOUND). Mitsubishi may select [*] Designated Compounds for each Target. If Mitsubishi does not identify any Designated Compound(s) within such period, then upon [*] notice from NeoGenesis and unless Mitsubishi identifies *= CONFIDENTIAL TREATMENT REQUESTED: MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. such Designated Compound(s) within such [*] period, the license granted Mitsubishi shall terminate and be of no further force or effect with respect to the applicable Target, and no further payment from Mitsubishi shall be due with respect to such Target.
(b) Within [*] following receipt of notification from Mitsubishi identifying Designated Compounds, NeoGenesis shall amend ATTACHMENT D to identify any applicable NeoGenesis Patent Rights not previously identified to Mitsubishi.